oligonucleotide probes

LASSO probes

The approach, published earlier this week in Nature Biomedical Engineering, uses long-adapter single-strand oligonucleotide (LASSO) probes.

The authors have plans to turn the technology into a kit for sequencing panels to be developed by their startup firm, Searna. 

The structured oligonucleotide probe could allow simultaneous PCR amplification and microarray hybridization, and could enable universal microarrays.

NEW YORK (GenomeWeb News) – Biosearch Technologies said today that it has acquired the oligonucleotide manufacturing division of DNA Technology for an undisclosed amount.

NEW YORK (GenomeWeb News) – AITbiotech has received ISO 13485:2003 certification for its labs in Singapore that offer genomics services and molecular diagnostic testing.

NEW YORK (GenomeWeb News) – Agilent Technologies today announced a deal with BioDiscovery allowing that firm's customers access to Agilent SureFISH probes directly from BioDiscovery's Nexus software.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Enzo Life Sciences this week sued Abbott, Becton Dickinson, and Hologic claiming those companies infringe Enzo's patent covering a method of modifying nucleotides for use as probes.

Biosearch has denied all allegations set forth by Life Technologies in a previously filed patent-infringement lawsuit revolving around the use of fluorescence-quenched oligonucleotide probes in PCR, diagnostics, and other DNA analysis applications.

IMDx received access to patents covering Biosearch's BHQ, CAL Fluor, and Quasar technologies.

In addition to licensing patents to DuPont, Biosearch will manufacture Scorpions primer oligonucleotides for DuPont's use in food diagnostics.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.